Author: BusinessWire

mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company p…

mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company p…

mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company p…

PORT WASHINGTON, N.Y.–(BUSINESS WIRE)–Aceto, a leading global virtual manufacturer of specialty materials for life sciences and advanced technology end markets, announced today the introduction of an expanded portfolio for biopharmaceutical and cell …

− More Than Three Times as Many Transplant Recipients With Confirmed Resistant Cytomegalovirus (CMV) Infection at Baseline Receiving the Investigational Drug Maribavir Achieved CMV Viremia Clearance Compared to Conventional Antiviral Therapies, Buildi…

Safety assessments completed for first 12 participants and no serious adverse events (SAEs) reported; trials expected to be fully enrolled in Q2

First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple r…

Increasing access and lowering costs for medicine used to treat immune-compromised patients
LAKE ZURICH, Ill.–(BUSINESS WIRE)–Fresenius Kabi announced today the immediate availability in the United States of Foscarnet Sodium Injection. Fresenius Kab…

Increasing access and lowering costs for medicine used to treat immune-compromised patients
LAKE ZURICH, Ill.–(BUSINESS WIRE)–Fresenius Kabi announced today the immediate availability in the United States of Foscarnet Sodium Injection. Fresenius Kab…

Safety assessments completed for first 12 participants and no serious adverse events (SAEs) reported; trials expected to be fully enrolled in Q2

First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple r…

Data Presented at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 21) Highlight Potential of Beta Adrenoceptor Agonists to Treat Neurodegenerative Disease
SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc….